Skip to main
OSTX
OSTX logo

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc is strategically positioned for growth in the oncology market, particularly with its focus on osteosarcoma, which presents a projected $500 million revenue opportunity for its lead asset, OST-HER2. The company benefits from financial stability that will support its operations through mid-2026, enabling it to pursue commercialization and partnership opportunities effectively. Furthermore, positive clinical data and granted patents significantly enhance OS Therapies' competitive position while bolstering its intellectual property assets, paving the way for potential regulatory approvals and market expansions.

Bears say

OS Therapies Inc. is currently facing challenges related to its clinical development timeline, which may be affecting investor confidence and overall market perception. Additionally, the company has reported significant cash burn rates associated with its research and development efforts, raising concerns about its financial sustainability and ability to fund ongoing projects. Lastly, with limited data on successful clinical outcomes and competition in the biopharmaceutical space, OS Therapies may struggle to attract further investment necessary for advancing its pipeline.

OSTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, OSTX has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.